Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Biomarin Pharmaceutical reported in-line EPS of $-0.32 versus an estimate of $-0.32.
Revenue was up $2.31 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.05 which was followed by a 9.04% increase in the share price the next day.
Here's a look at Biomarin Pharmaceutical's past performance:
| Quarter | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|
| EPS Estimate | -0.25 | -0.11 | -0.10 | -0.19 |
| EPS Actual | -0.20 | 0.07 | 0.09 | 0.12 |
| Revenue Estimate | 435.32M | 448.79M | 446.45M | 440.23M |
| Revenue Actual | 408.74M | 501.69M | 486.03M | 452.12M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
